Radiolabeled FAPI in pancreatic cancer: can it be an additional value in the management of patients?

Laura EvangelistaViviana Frantellizzi Orazio Schillaci Luca Filippi

Published in: Expert review of anticancer therapy (2023)

F]FDG. Preliminary data about the FAPI-based theragnostic approach in patients with pancreatic cancer (n=9 patients, totally) are now available. Radiolabeled-FAPI is a promising agent for the identification of pancreatic malignant lesions, but further prospective studies are still necessary.

Keyphrases

end stage renal disease
chronic kidney disease
newly diagnosed
ejection fraction
peritoneal dialysis
prognostic factors
pet imaging
big data
machine learning
electronic health record
patient reported outcomes
positron emission tomography
data analysis